Succinylcholine injection recalled after out-of-specification degradation impurity results
Zydus Succinylcholine Chloride Injection, USP, 200 mg/10 mL, is recalled after out-of-specification test results for an individual unknown degradation impurity. 270,125 vials are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Rubric level 3 covers risk-of-harm products where injury has not yet been reported; an injectable medicine outside its degradation impurity specification is a potential harm and no injuries are reported.
Plain-English summary
Succinylcholine Chloride Injection, USP, 200 mg/10 mL (20 mg/mL), in 10 mL multiple-dose sterile vials and available on prescription only, manufactured by Zydus Lifesciences Ltd in Vadodara, India and distributed by Zydus Pharmaceuticals (USA) Inc. of Pennington, New Jersey, is being recalled. Affected lots include L400077 expiring 8/31/2025, L400113 expiring 9/30/2025, L400372 and L400373 expiring 3/31/2026 and L400374. The recall covers 270,125 vials distributed in Mississippi, Ohio, Louisiana and Puerto Rico.
The recall was issued because the product failed impurities and degradation specifications, with out-of-specification test results obtained for an individual unknown degradation impurity. The FDA classified the action as Class II.
Hospitals and pharmacies holding these lots should quarantine them, stop using them, and follow the manufacturer's instructions for return or replacement.
The recalled product
- Product
- SUCCINYLCHOLINE CHLORIDE (SUCCINYLCHOLINE CHLORIDE)
- Brand
- SUCCINYLCHOLINE CHLORIDE
- Manufacturer
- Zydus Pharmaceuticals (USA) Inc
- Category
- Drug — Injectable
- Affected units
- 270,125
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot #s: L400077
- exp: 8/31/2025
- L400113
- exp.: 9/30/2025
- L400372
- L400373
- exp.: 3/31/2026
- L400374
- exp.: 4/30/2026.
Distribution
Related recalls
Same manufacturer · Zydus Pharmaceuticals (USA) Inc
See all →- SevereFDA Recalls Mirabegron Tablets Over Nitrosamine Impurity
FDA (Drugs) · 2026-08-12
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereErythromycin 500 mg Tablets Recalled for Impurity Above Limits
FDA (Drugs) · 2026-05-27
- HighIcosapent ethyl capsules recalled after active ingredient oxidized inside capsule
FDA (Drugs) · 2026-03-18
- HighIcosapent ethyl capsules recalled as subpotent after capsule contents leaked
FDA (Drugs) · 2026-01-28
Same hazard · failed specification
See all →- ModerateSodium iodide capsule packs recalled after failing capsule specifications
FDA (Drugs) · 2026-04-01
- HighMeclizine hydrochloride 12.5 mg tablets recalled after failing tablet specifications
FDA (Drugs) · 2026-04-01
- ModerateAmphetamine extended-release capsules 10 mg recalled over failed degradation specifications
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 20 mg recalled over impurity and degradation results
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 15 mg recalled after impurity testing failure
FDA (Drugs) · 2025-10-01